Ligand Pharmaceuticals price to free cash flow LGND

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 46.0×
10-year median: 24.2×
Against its 10-year history: 81st; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.4× to 132×
Peer median: 50.9×

Ligand Pharmaceuticals' price to free cash flow is 46.0× as of Oct 23, 2026.

That is above its ten-year median of 24.2×, higher than on 81% of days in the last ten years.

Over that time it ranged from 7.4× in Jun 2022 to 132× in Jan 2026.

The median for 10 large drugmakers of a similar size is 50.9×.

Price to free cash flow over time

median 24.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	46.0×	34.7×	132×
2025	125×	20.1×	130×
2024	27.5×	13.8×	58.1×
2023	13.9×	8.7×	13.9×
2022	12.0×	7.4×	14.6×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	23.4×	18.5×	26.3×
2017	21.7×	19.9×	26.3×
2016	24.6×	24.6×	40.5×
2015	n/m a value too high to mean anything
2014	40.0×	30.4×	92.4×
2013	64.9×	54.7×	309×
2012	58.1×	47.1×	60.2×

Against its peers

Companies in Drug Manufacturers - General nearest Ligand Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
LGNDLigand Pharmaceuticals	46.0×
KNSAKiniksa Pharmaceuticals International	32.7×
AMRXAmneal Pharmaceuticals	50.9×
ALKSAlkermes plc.	33.0×
TGTXTG Therapeutics	477×
PTGXProtagonist Therapeutics	68.6×
INDVIndivior Pharmaceuticals	n/m
CORTCorcept Therapeutics	86.8×
ARQTArcutis Biotherapeutics	100×
LQDALiquidia	25.3×
OGNOrganon	6.4×
Peer median	50.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Ligand Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.